TY - JOUR
T1 - Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry
AU - Schnorbus, Boris
AU - Wiebe, Jens
AU - Capodanno, Davide
AU - Brugaletta, Salvatore
AU - Geraci, Salvatore
AU - Mehilli, Julinda
AU - Latib, Azeem
AU - Lesiak, Maciej
AU - Jensen, Christoph
AU - Mattesini, Alessio
AU - Münzel, Thomas
AU - Capranzano, Piera
AU - Di Mario, Carlo
AU - Naber, Christoph
AU - Araszkiewicz, Aleksander
AU - Colombo, Antonio
AU - Caramanno, Giuseppe
AU - Sabate, Manel
AU - Tamburino, Corrado
AU - Nef, Holger
AU - Gori, Tommaso
N1 - Publisher Copyright:
© Europa Digital & Publishing 2017. All rights reserved.
PY - 2017/10
Y1 - 2017/10
N2 - Aims: The aim of this study was to report on the midterm outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD). Methods and results: One thousand four hundred and seventy-seven (1, 477) patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centres and were included in the GHOST-EU registry. Admissions comprised 47.1% of the patients (951 BVS) with ACS, and 52.8% (1, 274 BVS) with sCAD. During a median follow-up of 384 (359-460) days, patient-oriented endpoints (PoCE), including all-cause death, any infarction, any revascularisation, were recorded in 271 patients (12-month incidence in ACS patients: 18.5% vs. 11.6% in the sCAD group, p<0.001). Device-oriented composite endpoints (DoCE), cardiac death, target vessel infarction and target lesion revascularisation, were observed in 98 patients (12-month incidence of 4.2% in the sCAD group, 6.4% in the ACS group; p=0.052). The 12-month incidence of definite scaffold thrombosis was 2.6% in ACS patients and 0.8% in XIENCE patients (p=0.006). In multivariate analysis, ACS was a predictor of DoCE (HR: 2.26 [1.34-3.81], p=0.002), PoCE (HR: 1.71 [1.13-2.58], p=0.011), and stent thrombosis (HR: 2.51 [1.13-5.60], p=0.025). In contrast, the incidence of target lesion revascularisation was not different between groups. There was no difference in the incidence of any of these endpoints among the different clinical presentations (unstable angina, non-ST-elevation infarction and ST-elevation infarction). Conclusions: PoCE, DoCE and scaffold thromboses were more frequent in ACS patients, without any difference among different forms of ACS.
AB - Aims: The aim of this study was to report on the midterm outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD). Methods and results: One thousand four hundred and seventy-seven (1, 477) patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centres and were included in the GHOST-EU registry. Admissions comprised 47.1% of the patients (951 BVS) with ACS, and 52.8% (1, 274 BVS) with sCAD. During a median follow-up of 384 (359-460) days, patient-oriented endpoints (PoCE), including all-cause death, any infarction, any revascularisation, were recorded in 271 patients (12-month incidence in ACS patients: 18.5% vs. 11.6% in the sCAD group, p<0.001). Device-oriented composite endpoints (DoCE), cardiac death, target vessel infarction and target lesion revascularisation, were observed in 98 patients (12-month incidence of 4.2% in the sCAD group, 6.4% in the ACS group; p=0.052). The 12-month incidence of definite scaffold thrombosis was 2.6% in ACS patients and 0.8% in XIENCE patients (p=0.006). In multivariate analysis, ACS was a predictor of DoCE (HR: 2.26 [1.34-3.81], p=0.002), PoCE (HR: 1.71 [1.13-2.58], p=0.011), and stent thrombosis (HR: 2.51 [1.13-5.60], p=0.025). In contrast, the incidence of target lesion revascularisation was not different between groups. There was no difference in the incidence of any of these endpoints among the different clinical presentations (unstable angina, non-ST-elevation infarction and ST-elevation infarction). Conclusions: PoCE, DoCE and scaffold thromboses were more frequent in ACS patients, without any difference among different forms of ACS.
KW - ACS/NSTE-ACS
KW - Bioresorbable scaffolds
KW - Non-ST-elevation myocardial infarction (NSTEMI)
KW - ST-elevation myocardial infarction (STEMI)
UR - http://www.scopus.com/inward/record.url?scp=85026736136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026736136&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-16-00568
DO - 10.4244/EIJ-D-16-00568
M3 - Article
C2 - 28320687
AN - SCOPUS:85026736136
SN - 1774-024X
VL - 13
SP - e1104-e1111
JO - EuroIntervention
JF - EuroIntervention
IS - 9
ER -